CNMD logo

CONMED CORP

CNMDNYSE
πŸ† #2242 by market capEarnings Oct 28 Β· PostUS Equity
$615.55β–² $29.85 (+4.85%)
Simulated price
πŸ””
Track CNMD
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 4.8%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$1.40B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+3.4%
Slowing
πŸ“ŠGross Margin
55.8%
Healthy
πŸ’΅FCF Margin
9.8%
Moderate
βš–οΈP/S Ratio
1.0x
Cheap
Otter Score
72
Fair
No chart data available for CNMD.

Trading Snapshot

Day Range
$607.35 – $620.88
52-Week Range
$31.44 – $53.66
Volume
$4.26B
Avg Volume
$5.04B
Shares Outstanding
29.9M
Next Earnings
Dec 10, 2026

Fundamentals Snapshot

Annual Revenue
$1.37B
Last Q Revenue
$343M
P/E Ratio
24.7
P/S Ratio
1.0x
EPS (TTM)
$1.85
Dividend Yield
0.89%
Dilution (1yr)
βˆ’0.3%

Why Investors Own CNMD

  • βœ“High-growth profile β€” revenue up +53.9% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 52% gross margin and 20% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CNMD logo

CONMED CORP

CNMD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1.4Bβ–² +5.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
52.8%β–Ό βˆ’5.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$141Mβ–Ό βˆ’29.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$151Mβ–Ό βˆ’2.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
31.0Mβ–Ό βˆ’0.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$794Mβ–² +$87M YoY
StockOtter Β· stockotter.space

About CONMED CORP

CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
72/100

Analyst Price Target

β“˜
Average Target
$702.62
β–² +14.1% Upside
High Target$783.75
Low Target$609.41
Based on 23 analysts

Latest News & Updates